Disc Medicine Terminates Material Definitive Agreement
Ticker: IRON · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1816736
| Field | Detail |
|---|---|
| Company | Disc Medicine, Inc. (IRON) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $200.0 million, $22.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, filing
TL;DR
Disc Medicine just terminated a major deal, filing an 8-K today.
AI Summary
On November 15, 2024, Disc Medicine, Inc. filed an 8-K detailing the termination of a material definitive agreement. The filing also includes information on financial statements and exhibits.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction and financial performance.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can indicate underlying issues or strategic shifts that carry inherent business risks.
Key Players & Entities
- Disc Medicine, Inc. (company) — Registrant
- November 15, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 001-39438 (identifier) — Commission File Number
- 321 Arsenal Street, Suite 101, Watertown, MA 02472 (address) — Principal executive offices
- Gemini Therapeutics, Inc. (company) — Former company name
- FS Development Corp. (company) — Former company name
FAQ
What specific material definitive agreement was terminated by Disc Medicine, Inc.?
The provided filing excerpt does not specify the exact name or details of the terminated material definitive agreement.
What are the implications of this termination for Disc Medicine's ongoing operations?
The filing does not detail the specific implications for Disc Medicine's ongoing operations, only that the agreement was terminated.
When was the material definitive agreement entered into?
The filing does not provide the entry date of the terminated material definitive agreement.
Are there any financial consequences mentioned due to this termination?
The provided excerpt does not mention any specific financial consequences resulting from the termination.
What other items are included in this 8-K filing besides the agreement termination?
This 8-K filing also includes information on Financial Statements and Exhibits.
Filing Stats: 1,136 words · 5 min read · ~4 pages · Grade level 10.8 · Accepted 2024-11-15 16:31:29
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share IRON The Nasdaq Global Ma
- $200.0 million — ng an aggregate offering price of up to $200.0 million by the Company under the Agreement (the
- $22.5 million — reement for aggregate gross proceeds of $22.5 million. The Company is not subject to any term
Filing Documents
- d913169d8k.htm (8-K) — 32KB
- d913169dex11.htm (EX-1.1) — 230KB
- d913169dex51.htm (EX-5.1) — 8KB
- 0001193125-24-259855.txt ( ) — 455KB
- iron-20241115.xsd (EX-101.SCH) — 3KB
- iron-20241115_lab.xml (EX-101.LAB) — 18KB
- iron-20241115_pre.xml (EX-101.PRE) — 11KB
- d913169d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Controlled Equity Offering SM Sales Agreement dated November 15, 2024 by and between Disc Medicine, Inc. and Cantor Fitzgerald & Co. 5.1 Opinion of Goodwin Procter LLP 23.1 Consent of Goodwin Procter LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: November 15, 2024 By: /s/ John Quisel Name: John Quisel, J.D. Ph.D. Title: Chief Executive Officer